Fremanezumab Terminated Phase 3 Trials for Episodic Cluster Headache Treatment

IndicationsStatusPurposePhase
TerminatedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02945046A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)